Mounjaro®
Starting from £179.99/mo
Start journey Learn moreIf you have high blood pressure and are considering Wegovy, the short answer is that raised blood pressure is actually listed as one of the weight-related conditions that can make you eligible — and clinical trial data suggest semaglutide tends to lower blood pressure as weight falls. That said, high blood pressure also appears on the list of conditions that require careful prescriber assessment before starting treatment, because individual circumstances vary considerably. Wegovy (semaglutide) is a prescription-only medicine; a GPhC-registered prescriber reviews your full health picture before any treatment is approved.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
This is a question our prescribers hear most weeks, and the answer is genuinely nuanced. Under Wegovy's UK licence, hypertension counts as a weight-related comorbidity, so if your BMI is 27 or above and high blood pressure is one of your conditions, you may meet the licensed criteria for semaglutide as a weight-management medicine. The full picture of what Wegovy is and how it's used in the UK covers the licensing detail in more depth.
Eligibility isn't a simple checklist, though. A prescriber also needs to know whether your blood pressure is currently controlled, which medicines you're on, and whether any contraindications applies. Uncontrolled, severe hypertension, for example, changes the risk calculation. So while having high blood pressure is not a flat barrier to treatment, it does make thorough clinical assessment essential, not optional. That's why every Wegovy prescription at a regulated pharmacy follows a personal review, not an automated tick-box.
Lower BMI thresholds can apply for some ethnic backgrounds under UK guidance, so the 27 kg/m² figure isn't universal. If you're close to the boundary, it's worth raising that in your consultation rather than ruling yourself out in advance.
The honest answer is that the dominant effect seen in trials is a reduction. Blood pressure tends to fall as weight falls, and weight loss is Wegovy's primary mechanism of action. The semaglutide overview page explains the GLP-1 pathway in detail, but in practical terms: as the body carries less weight, the heart works under less strain and vascular resistance tends to decrease.
In the STEP 1 trial, published in the New England Journal of Medicine, participants taking semaglutide 2.4mg lost around 15% of body weight on average over 68 weeks alongside lifestyle changes. Reductions in systolic blood pressure were reported as part of the cardiometabolic improvements seen. The effect isn't dramatic in isolation (we're not talking about Wegovy as a blood pressure drug) but for people whose hypertension is partly driven by excess weight, the two benefits compound each other.
There's a more detailed look at how Wegovy affects blood pressure specifically if you want the numbers broken down further. Worth reading alongside this page.
Low blood pressure is less commonly discussed than the gastrointestinal side effects that get most of the attention, but it's a legitimate clinical consideration, particularly for people already on antihypertensive medicines. As weight falls and blood pressure responds, a dose that was previously appropriate may become too strong. The result can be lightheadedness, dizziness on standing, or fatigue.
This isn't a reason to avoid treatment; it's a reason to keep your prescribing team informed. Anyone taking antihypertensive medication should flag this at the outset of a Wegovy consultation and mention any symptoms during treatment. Prescribers can liaise with your GP about adjusting your hypertension medicine if needed. The NHS guidance on weight-management injections specifically highlights this coordination point.
If you're curious about the lower end of the blood pressure spectrum and what to watch for, semaglutide and low blood pressure covers the signs to take seriously. The standard common side effects (nausea, mild dizziness during titration, headache) are distinct from a sustained drop in blood pressure, and it's worth knowing the difference before you start.
At a GPhC-registered online pharmacy, the consultation process asks specifically about existing health conditions, current medications and recent monitoring. For someone with high blood pressure, that means noting your antihypertensive medicines, whether your blood pressure is controlled, and any relevant history. A GPhC-registered Independent Prescriber reads those answers personally on the day you submit, the same day, not the following week.
If treatment is clinically appropriate, your prescription is issued and your medication is dispatched the same day (for orders placed before 12pm, Monday to Friday), arriving the next working day by tracked DPD delivery in plain packaging. The guide to getting Wegovy in the UK explains how to verify that any pharmacy you use is properly registered, and if you're exploring other combinations such as using anavar alongside semaglutide, that's a separate area worth reviewing with a prescriber before making any decisions.
Ongoing monitoring matters too. Blood pressure isn't something to check once and forget once treatment starts. Our clinical team provides aftercare seven days a week, and repeat prescriptions are only issued after a clinical re-review, so changes in your condition are caught, not overlooked. If you're ready to discuss your situation with a prescriber, start your free consultation here.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.